Testing effectiveness (Phase 2)Study completedNCT04827719
What this trial is testing
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 38